The termination removes a significant future revenue stream from PRX019, increasing reliance on the moponetug program for milestone and royalty income. Monitor Bristol Myers Squibb's Phase 2 TargetTau-1 trial data for moponetug, as its success is now critical to Prothena's pipeline value.
Price Chart
Executive Summary
Bristol Myers Squibb terminated the PRX019 global license agreement after an internal strategic review, deciding not to advance the candidate further in the clinic. Prothena loses access to up to $617.5 million in development, regulatory, and sales milestones plus tiered royalties, though it retains the $80 million upfront payment received in May 2024. The ongoing moponetug (PRX005) collaboration for Alzheimer's disease remains unaffected.
Key Facts
- Bristol Myers Squibb informed Prothena on October 28, 2026 that it will not advance PRX019 further in the clinic.
- The PRX019 Global License Agreement will terminate on January 28, 2027.
- Prothena received an $80 million upfront payment in May 2024 under the agreement.
- Prothena was eligible for up to $617.5 million in development, regulatory, and sales milestones, plus tiered royalties, all of which are now forfeited.
- Phase 1 trial for PRX019 completed in H1 2026 with benign safety and tolerability, no immunogenicity, and dose-dependent PK/PD meeting prespecified targets.
- Bristol Myers Squibb continues to develop moponetug (PRX005) for Alzheimer's disease, with $135 million in licensing payments received to date and up to $562.5 million in remaining milestones.
- Prothena's market cap is approximately $452 million.
Financial Impact
Forfeiture of up to $617.5 million in potential milestones and tiered royalties on worldwide net sales of PRX019; the $80 million upfront payment is retained.
Risk Factors
- Loss of up to $617.5 million in potential milestones and royalties from PRX019.
- Increased dependence on the moponetug Alzheimer's program, which is still in Phase 2 and carries clinical and regulatory risk.
- No termination fees or payments are owed by Bristol Myers Squibb.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001559053-26-000026 |
| Document: 0001559053-26-000026-index-headers.html | 0001559053-26-000026 |
| Document: 0001559053-26-000026-index.html | 0001559053-26-000026 |
| Document: 0001559053-26-000026.txt | 0001559053-26-000026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $9.10 | awaiting T+1 | awaiting T+1 | $8.47 (+6.92%) |
Oct 26, 2026 6d ago | Insider Buy | $8.81 $9.10 | ▲ +3.29% | ▲ +2.95% | $8.47 (−3.86%) |
Oct 15, 2026 17d ago | Insider Buy | $8.35 $8.48 | ▲ +1.56% | ▲ +1.13% | $8.47 (+1.44%) |
Sep 30, 2026 4w ago | Insider Buy | $8.54 $8.36 | ▼ −2.11% | ▼ −2.85% | $8.47 (−0.82%) |
Sep 29, 2026 4w ago | Insider Buy | $8.38 $8.54 | ▲ +1.91% | ▲ +1.73% | $8.47 (+1.07%) |
Sep 21, 2026 5w ago | Insider Buy | $8.99 $8.68 | ▼ −3.45% | ▼ −2.73% | $8.47 (−5.78%) |
Sep 3, 2026 8w ago | Insider Buy | $9.82 $9.54 | ▼ −2.85% | ▼ −2.30% | $8.47 (−13.75%) |
Aug 21, 2026 10w ago | Insider Buy | $9.45 $9.39 | ▼ −0.63% | ▼ −0.34% | $8.47 (−10.37%) |
Aug 10, 2026 11w ago | Insider Buy | $9.12 $9.22 | ▲ +1.10% | ▲ +1.42% | $8.47 (−7.13%) |
Jul 30, 2026 13w ago | Insider Cluster | $8.12 $8.33 | ▲ +2.59% | ▲ +1.16% | $8.47 (+4.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers